Centessa Pharmaceuticals plc Share Price & Technical Analysis
CNTA · $39.58 (-0.08%)
Healthcare / Biotechnology
$39.58
-0.08%
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersom…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
1% return in May, -4% avg return in past 3 year May month.
57% return in 2026, 84% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -1% | 9% | 49% | -1% | 1% | – | – | – | – | – | – | – | 57% |
| 25 | 1% | -5% | -8% | -4% | -1% | -4% | 32% | -2% | 44% | 3% | 16% | -16% | 57% |
| 24 | 3% | 28% | 8% | -20% | -7% | 3% | 17% | 27% | 18% | -6% | 18% | -6% | 83% |
| 23 | 25% | -12% | 9% | 24% | -4% | 38% | 25% | -4% | -16% | 3% | -6% | 31% | 112% |
| 22 | -15% | -8% | 2% | -3% | -49% | 9% | -12% | 0% | -7% | 0% | 0% | -21% | -104% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Strong
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$6.13B
P/E ratio
—
52W high
$40.26
52W low
$10.95
Volume
16,67,955
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Centessa Pharmaceuticals plc share price today?
- Centessa Pharmaceuticals plc (CNTA) last traded around $39.58 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CNTA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CNTA. Download the app for real-time alerts.
- How can I analyze Centessa Pharmaceuticals plc stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.